^
Association details:
| Biomarker: | KMT2A rearrangement |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | ziftomenib (KO-539) (Menin-MLL inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Excerpt:
...- Has a documented NPM1 mutation or KMT2A rearrangement....
Trial ID:
Source:
Title:
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients With AML
Excerpt:
...- Patients must have a documented NPM1 mutation or KMT2A rearrangement and have either newly diagnosed or relapsed/refractory AML...
Trial ID:
More C2 evidence
Source:
Title:
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
Excerpt:
...Patients with a documented lysine[K]-specific methyltransferase 2-rearrangement (KMT2A-r), or 2....
Trial ID:
Less C2 evidence
Source:
Title:
64 Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Published date:
11/03/2022
Excerpt:
We present here preliminary KOMET-001 (NCT04067336) data, an ongoing Phase (P) 1/2 study of ziftomenib (KO-539), an inhibitor of KMT2A-menin interaction, in adult pts with relapsed/refractory (R/R) AML….At 600 mg, 1 of 2 KMT2Ar pts had stable disease with significantly decreased BC lasting >4 months.
DOI:
https://doi.org/10.1182/blood-2022-167412
Trial ID:
